NEW YORK (360Dx) – Startup Octave Bioscience has closed a $14 million Series A round of financing, which will fund the firm's efforts to develop a platform for the management of patients with multiple sclerosis.
Launched two years ago by William Hagstrom, formerly the CEO of rheumatoid arthritis testing firm Crescendo Bioscience, Octave aims to integrate protein biomarker measurements, data from patient wearables, and imaging to improve management of MS.